Clinical Trial Update: A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Eloralintide (LY3841136) alone and with tirzepatide in adults with overweight or obesity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Eloralintide (LY3841136)
• Tirzepatide (tirzepatide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Overweight, Obesity | Phase 1 | Status: COMPLETED